IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dai…
$704.23+0.89%
报价 2026-11-13
市值
$55.48B
EV
$56.45B
PE (TTM)
47.6x
预期 PE (FY2026)
47.2x
52 周区间距高点 -8.1%
$504.70$766.68
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 14.78 → 16.84（1.1x） | 41.8 |
| FY+32028-12 | 1.2x | 14.78 → 19.16（1.3x） | 36.8 |
毛利率 63% · TTM 收入 $4662M · 基数 EPS 14.78（调整后）
电话会信号
辅助标签Q3 20262026-11-02
AI 词频高上调指引
指引 上调
信心 5
分析师 4
“We are on track to exceed both our 5,500 inVue Dx placement goal for the year and our five-year goal of 20,000 placements.”
原文引用（1）
- 上调指引：We are raising our full year revenue range to $4.741 billion-$4.767 billion, an increase of $32 million at midpoint
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IDXXIDEXX Laboratories, Inc. | $55.48B | +0.9% | +10.8% | 62.9% | 47.6x | 33.7x | 42.8x | |
| CORCencora, Inc. | $68.51B | +3.0% | +4.6% | 4.3% | 23.2x | 13.6x | 15.1x | |
| CAHCardinal Health, Inc. | $64.97B | +1.1% | +4.1% | 4.3% | 31.6x | 16.9x | 11.9x | |
| EWEdwards Lifesciences Corporation | $61.61B | +1.3% | +12.7% | 78.1% | 44.5x | 32.6x | 43.3x | GARP |
| ARGXargenx SE | $60.29B | -2.2% | – | 89.9% | 38.2x | 39.0x | 58.5x | |
| BDXBecton, Dickinson and Company | $59.39B | +1.1% | +2.4% | 45.8% | 25.3x | 14.7x | 21.1x | |
| AAgilent Technologies, Inc. | $49.05B | +0.5% | +6.5% | 26% | 27.1x | 23.0x | 34.2x | |
| VEEVVeeva Systems Inc. | $48.82B | -0.3% | +16.5% | 75% | 48.9x | 36.6x | 29.9x | |
| IQVIQVIA Holdings Inc. | $43.69B | -2.2% | +8.0% | 32.9% | 33.1x | 16.6x | 16.9x | |
| 同行中位数 | – | – | +6.5% | 39.3% | 32.3x | 20.0x | 25.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.22B | $1.14B | $1.09B | $1.11B | $1.11B | $998.4M | $954.3M |
| Gross Margin | 62.9% | 64% | 63.4% | 60.3% | 61.8% | 62.6% | 62.4% | 59.8% |
| Operating Margin | 33.1% | 35% | 31.8% | 28.9% | 32.1% | 33.6% | 31.7% | 27.4% |
| Net Income | $317.1M | $338.4M | $278.4M | $248.2M | $274.6M | $294M | $242.7M | $216.1M |
| Diluted EPS | 4.01 | 4.19 | 3.45 | 3.08 | 3.4 | 3.63 | 2.96 | 2.62 |
| Operating Cash Flow | $449.7M | $347.2M | $266.2M | $352M | $402.3M | $185.7M | $238M | $262M |